Torisel (temsirolimus) / Pfizer 
Welcome,         Profile    Billing    Logout  
 366 Diseases   39 Trials   39 Trials   1689 News 
45 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
2011-001113-14: Pharmakokynetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients Estudio farmacocinético y farmacodinámico de temsirolimus en pacientes con carcinoma de células renales.

Ongoing
4
10
Europe
TORISEL 30 mg, concentrado y disolvente para solución para perfusión., TORISEL 30 mg, concentrado y disolvente para solución para perfusión.
Fundación Hospital Clinic i Provincial, Pfizer S.L.U.
Renal Cell Carcinoma Patients Pacientes con carcinoma de células renales.
 
 
PRL-SRL-IHHE, NCT04406870: Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)

Not yet recruiting
4
36
RoW
Sirolimus Oral Product, TORISEL, rapamycin, propranolol, xin de an (chinese name means making me comfortable)
Shanghai Children's Medical Center
Hemangioendothelioma of Liver
06/24
06/25
NCT02265692: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Recruiting
3
253
US, Canada, RoW
therapeutic conventional surgery, cisplatin, CACP, CDDP, CPDD, DDP, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, doxorubicin hydrochloride, ADM, ADR, Adria, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, liver transplantation, laboratory biomarker analysis
National Cancer Institute (NCI)
Childhood Hepatoblastoma, Stage I Childhood Liver Cancer, Stage II Childhood Liver Cancer, Stage III Childhood Liver Cancer, Stage IV Childhood Liver Cancer
06/16
 
NCT00980460: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Active, not recruiting
3
236
Canada, Japan, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Dexrazoxane, 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI), 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI), ADR 529, ADR-529, ADR529, ICRF 187, ICRF-187, ICRF187, Razoxane (+)-form, Soluble ICRF (L-isomer), Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Laboratory Biomarker Analysis, Liver Transplantation, Hepatic Transplantation, Liver Grafting, Liver Transplant, Transplantation of Liver, Temsirolimus, CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
06/20
03/25
ARST1431, NCT02567435: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Active, not recruiting
3
325
Canada, US, RoW
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
National Cancer Institute (NCI)
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
06/23
10/24
TANGO-3, NCT04433572: Temsirolimus Adventitial Delivery to Improve ANGioplasty And/or Atherectomy Revascularization Outcomes Below the Knee

Not yet recruiting
3
250
NA
Temsirolimus, Saline placebo
Mercator MedSystems, Inc.
Peripheral Artery Disease, Critical Limb Ischemia
12/27
06/32
NCT00061971: Letrozole With or Without CCI-779 in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
2
US
letrozole, temsirolimus
University Hospitals Seidman Cancer Center, National Cancer Institute (NCI)
Breast Cancer
 
 
NCT00977574: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
2
349
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Onbevzi, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Temsirolimus, CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Cancer, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
01/15
03/25
NCT01396408: A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Active, not recruiting
2
137
Canada
Sunitinib, Temsirolimus
Canadian Cancer Trials Group, Pfizer
Advanced Rare Tumours
07/15
12/24
NCT01946529: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Active, not recruiting
2
24
US
vincristine, Oncovin(R), doxorubicin, Adriamycin(R), cyclophosphamide, Cytoxan(R), ifosfamide, Ifex(R), etoposide, VP-16, Vepesid(R), temozolomide, Temodar(R), temsirolimus, CCI-779, Torisel^TM, bevacizumab, rhumab VEGF, Avastin(R), sorafenib, BAY-43-9006, Nexavar(R), surgery, therapeutic conventional surgery, radiation, proton beam radiation therapy, external beam radiation therapy, brachytherapy
St. Jude Children's Research Hospital, University of Tennessee, University of Florida, Nemours Children's Clinic
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
08/15
07/26
2008-003328-45: Klinisk utvecklingsarbete för utvärdering av molykulärt riktad behandling vid metastaserande njurcancer- PETTO

Ongoing
2
20
Europe
TORISEL, (Temsirolimus), EMEA/H/C/799/001, Torisel, Torisel
Sahlgrenska Universitetssjukhuset
Metastaserande njurcancer
 
 
2008-000928-71: “TWIST”. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008

Ongoing
2
68
Europe
Temsirolimus, CCI-779, ROFERON A, ROFERON A
GRUPPO ONCOLOGICO ITALIANO DI RICERCA
Patients with advanced non-clear Cell Renal Carcinoma.
 
 
2008-006798-33: Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENESIS INHIBITORS

Ongoing
2
120
Europe
Concentrate for solution for infusion
CONSORZIO ONCOTECH
Patients with metastatic RCC
 
 
2008-008478-30: [Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus]Target-specific therapy of metastatic urothelial carcinoma with temsirolimus

Ongoing
2
26
Europe
Temsirolimus, Torisel, Torisel
Lukaskrankenhaus GmbH
Chemotherapy refractory metastatic urothelia carcinoma
 
 
NCT01517243: Phase II Study of Alternating Sunitinib and Temsirolimus

Completed
2
37
US
Sunitinib, Sutent, Temsirolimus, TORISEL®
Dartmouth-Hitchcock Medical Center
Metastatic Renal Cell Carcinoma
08/18
08/18
TAP-DANCE, NCT03942601: Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

Terminated
2
10
US
Temsirolimus, Temsirolimus and dexamethasone sodium phosphate
Mercator MedSystems, Inc.
Peripheral Arterial Disease
04/21
04/21
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
2015-005437-53: Study into the safety and activity of the drug Crizotinib for children with malignant tumors

Ongoing
1/2
94
Europe, RoW
Xalkori 200 mg hard capsules, Xalkori 250 mg hard capsules, Xalkori 150 mg hard capsules, Xalkori oral solution, Torisel 30 mg concentrate and diluent for solution for infusion temsirolimus, PF-02341066, L01XE09, Capsule, hard, Oral solution, Concentrate and solvent for concentrate for solution for infusion, Xalkori 200 mg hard capsules, Xalkori 250 mg hard capsules, Torisel 30 mg concentrate and diluent for solution for infusion temsirolimus
Erasmus Medical Center, Pfizer BV, Cancer Research UK, Erasmus MC,
Malignancies carrying a genetic alteration of ALK, MET or ROS1, Genetic alteration in tumor tissue leading to a magnified growth of tumor cells., Diseases [C] - Cancer [C04]
 
 
NOA-20, NCT03158389 / 2015-002752-27: NCT Neuro Master Match - N²M²

Completed
1/2
228
Europe
APG101, Alectinib, Alecensa, Idasanutlin, Atezolizumab, Vismodegib, Erivedge, Temsirolimus, Troisel, Palbociclib, Ibrance
University Hospital Heidelberg, German Cancer Aid, German Cancer Research Center, National Center for Tumor Diseases, Heidelberg
Glioblastoma, Adult
02/23
02/23
NCT05144698: RAPA-201 Therapy of Solid Tumors

Recruiting
1/2
22
US
RAPA-201 Rapamycin Resistant T Cells, RAPA-201 cells, Chemotherapy Prior to RAPA-201 Therapy
Rapa Therapeutics LLC
Solid Tumor, Breast Cancer, Small Cell and Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Gastric Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Carcinoma of Unknown Primary, Bladder Cancer, Malignant Melanoma
01/24
12/24
NCT04650451: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Suspended
1/2
220
US
chimeric antigen receptor (CAR) T cell therapy, CAR-T, BPX-603, autologous CAR-T
Bellicum Pharmaceuticals
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
12/25
01/27
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Active, not recruiting
1
140
US
AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus
AstraZeneca
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
08/10
12/24
NCT01013519: Temsirolimus and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer and Liver Dysfunction

Checkmark Temsirolimus + sorafenib
Mar 2013 - Mar 2013: Temsirolimus + sorafenib
Checkmark P1 interim data
Jan 2011 - Jan 2011: P1 interim data
Active, not recruiting
1
25
US
sorafenib tosylate, temsirolimus, laboratory biomarker analysis, pharmacological study
University of California, San Francisco, National Cancer Institute (NCI)
Hepatic Complications, Liver Cancer
12/13
03/14
NCT02344147: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
30
US
Ixabepilone, BMS 247550, BMS-247550, Temsirolimus, CCI-779, Torisel, Pharmacological Study, pharmacological studies
Mayo Clinic, National Cancer Institute (NCI)
Adult Solid Neoplasm
06/16
 
NCT02238496: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Completed
1
10
US
Cytoreductive surgery, Resection, Perifosine, AEZS-104/D-21266, KRX-0401, Temsirolimus, Torisel
Andrew B Lassman, MD, Pfizer, AEterna Zentaris
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
10/17
02/21
NCT01375829: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
22
US
Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Pharmacological Study, Temsirolimus, CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Solid Neoplasm
06/18
03/25
NCT01087554: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
1
249
US
Sirolimus, Rapamune, Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Everolimus, Afinitor, Zortress, RAD001, Temsirolimus, CCI-779, Torisel
M.D. Anderson Cancer Center
Advanced Cancer
08/26
08/26
FLT-PET, NCT00880074: in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Completed
1
10
US
Fluorothymidine F-18, 18F-FLT, 3'-Deoxy-3'-(18F) Fluorothymidine, 3'-deoxy-3'-[18F]fluorothymidine, ALOVUDINE F-18, Fluorothymidine F 18, Laboratory Biomarker Analysis, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Neoplasm
02/22
02/22
NCT02389309: Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

Active, not recruiting
1
14
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dasatinib, BMS-354825, Sprycel, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Brain Neoplasm
10/24
10/24
NCT02420613: Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma

Active, not recruiting
1
18
US
Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Diffuse Intrinsic Pontine Glioma
10/24
10/24
NCT01552434: Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease

Active, not recruiting
1
155
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Cetuximab, Cetuximab Biosimilar CMAB009, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Valproic Acid, Depakene, Stavzor, Valproate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC V7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC V7, Stage IIIB Breast Cancer AJCC V7, Stage IIIC Breast Cancer AJCC V7, Stage IV Breast Cancer AJCC V6 and V7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
03/26
03/26
NCT01187199: Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Active, not recruiting
1
278
US
Temsirolimus, CCI-779, Torisel, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Paclitaxel, Taxol, Sorafenib, Nexavar, BAY 43-9006, Carboplatin, Paraplatin
M.D. Anderson Cancer Center
Advanced Cancer
04/26
04/26
NCT05773326: Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

Recruiting
1
12
US
Temsirolimus, Torisel
Nader Sanai, Barrow Neurological Institute, Ivy Brain Tumor Center
High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
04/25
04/26
NCT01529593: Temsirolimus in Combination with Metformin in Patients with Advanced Cancers

Active, not recruiting
1
87
US
Temsirolimus, CCI-779, Torisel, Metformin
M.D. Anderson Cancer Center
Advanced Cancers
06/26
06/26
Metronomic, NCT02446431: Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

Recruiting
1
20
US
Bevacizumab, Avastin, Cyclophosphamide, Cytoxan, Valproic Acid, Depakote, Temsirolimus, Torisel
Miller Children's & Women's Hospital Long Beach, Children's Hospital of Orange County
Solid Tumor
07/24
07/29
NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Not yet recruiting
1
20
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
12/25
12/25
NCT03203525: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Recruiting
1
52
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Tumor Treating Fields Therapy, Alternating Electric Field Therapy, TTF, TTFields
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
12/26
12/26
ChiCTR1800020309: Autophagy mechanism of ovarian EMs cells with intervention of Luo's prescription for endometriosis based on PI3K/Akt/mTOR signaling pathway: an in vitro study

Not yet recruiting
N/A
200
 
None ;Luo 's prescription for endometriosis ;Luo 's prescription for endometriosis ;Luo 's prescription for endometriosis ;Danazol ;Danazol ;Danazol ;Temsirolimus ;Temsirolimus ;Temsirolimus
The First Affiliated Hospital of Guangzhou University of Chinese Medicine; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Traditional Chinese Medicine Bureau Of Guangdong Province
Endometriosis
 
 
NCT03724097: Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Active, not recruiting
N/A
200
US, RoW
RNA sequencing, RNA-seq, Transcriptome analysis, target drug with the score above 0,1, target drug with the score equal or below 0,1, non-target drug, palliative care
OmicsWay Corp., Oncobox Ltd, Vitamed LLC, N.N. Blokhin National Medical Research Center of Oncology, Kaluga Regional Clinical Oncology Center, Multidisciplinary medical holding SM-Clinic, Oncological Clinical Dispensary No. 1 of the Moscow City Health Department
Cancer
04/21
11/22
COMBOREIN, NCT03571438: Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors

Recruiting
N/A
100
Europe
CK2 and ATM inhibitors serine/ threonin Kinase combination, Sunitinib, Pazopanib, Temsirolimus
University Hospital, Grenoble
Kidney Cancer
09/22
09/24
PDXovo, NCT04602702: Hyper-Personalized Medicine Using Patient Derived Xenografts () for Metastatic Solid Tumors

Recruiting
N/A
50
Canada
Sunnybrook Health Sciences Centre
Kidney Neoplasm, Carcinoma, Renal Cell, Metastatic Solid Tumor
12/22
12/22
ALLTARGETOBS, NCT05832125: Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia

Recruiting
N/A
80
Europe
Versailles Hospital
Relapsed/Refractory Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Leukemia
12/23
03/24
NCT05406154: Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Recruiting
N/A
60
RoW
Peking University Third Hospital, Peking Union Medical College Hospital, The Second Affiliated Hospital of Dalian Medical University, Peking University First Hospital, Beijing Tongren Hospital, Beijing Hospital, Beijing Tsinghua Changgeng Hospital, China-Japan Friendship Hospital, 307 Hospital of PLA, Chinese PLA General Hospital, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Baotou Cancer Hospital, Beijing Shijitan Hospital, Capital Medical University, Shanxi Province Cancer Hospital, Beijing Naval General Hospital, First Hospital of China Medical University, Jilin Provincial Tumor Hospital, Shengjing Hospital
Mantle Cell Lymphoma (MCL)
12/23
07/24
NCT05429918: Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

Recruiting
N/A
60
RoW
Peking University Third Hospital, The Second Affiliated Hospital of Dalian Medical University, Peking University First Hospital, Beijing Hospital, Beijing Tsinghua Changgeng Hospital, China-Japan Friendship Hospital, Chinese PLA General Hospital, First Affiliated Hospital of Harbin Medical University, Baotou Cancer Hospital, Beijing Shijitan Hospital, Capital Medical University, Shanxi Province Cancer Hospital, Beijing Naval General Hospital, First Hospital of China Medical University, Jilin Provincial Tumor Hospital, Shengjing Hospital, 307 Hospital of PLA, Peking Union Medical College Hospital, Harbin Medical University, Beijing Tongren Hospital
Mantle Cell Lymphoma
12/23
06/24

Download Options